Search results for "BIOINFORMATICS"

showing 10 items of 1632 documents

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice

2018

Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors effica…

0301 basic medicineCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentProgrammed Cell Death 1 Receptorimmune checkpoint inhibitorDiseaseNSCLCBioinformaticsB7-H1 Antigenimmune checkpoint inhibitorsTranslational Research Biomedical0302 clinical medicineCarcinoma Non-Small-Cell LungPD-1clinical studiesNSCLC; PD-1; PD-L1; biomarkers; cancer immunogenicity; clinical studies; immune checkpoint inhibitors; translational researchMolecular Targeted TherapybiologyImmunogenicityGeneral Medicinecancer immunogenicityOncology030220 oncology & carcinogenesisbiomarkerCytokinesImmunotherapyPD-L1chemical and pharmacologic phenomena03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemPD-L1Biomarkers TumormedicineHumansLung cancerbusiness.industryImmunitybiomarkersCancerImmunotherapymedicine.disease030104 developmental biologytranslational researchTumor EscapeMutationbiology.proteinTumor Escapebusinessclinical studieFuture Oncology
researchProduct

Concepts to Target MYC in Pancreatic Cancer.

2016

Abstract Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. Mol Cancer Ther; 15(8); 1792–8. ©2016 AACR.

0301 basic medicineCancer ResearchPoor prognosisPancreatic ductal adenocarcinomaendocrine system diseasesGene regulatory networkAntineoplastic AgentsBiologymedicine.disease_causeBioinformaticsProto-Oncogene Proteins c-myc03 medical and health sciencesPancreatic cancerCarcinomamedicineAnimalsHumansGene Regulatory NetworksMolecular Targeted TherapyProtein Kinase InhibitorsCancerGenetic Variationmedicine.diseasedigestive system diseasesGene Expression Regulation NeoplasticPancreatic Neoplasms030104 developmental biologyOncologyCarrier proteinCancer researchKRASCarrier ProteinsCarcinoma Pancreatic DuctalProtein BindingSignal TransductionMolecular cancer therapeutics
researchProduct

Preclinical models for precision oncology

2018

Precision medicine approaches have revolutionized oncology. Personalized treatments require not only identification of the driving molecular alterations, but also development of targeted therapies and diagnostic tests to identify the appropriate patient populations for clinical trials and subsequent therapeutic implementation. Preclinical in vitro and in vivo models are widely used to predict efficacy of newly developed treatments. Here we discuss whether, and to what extent, preclinical models including cell lines, organoids and tumorgrafts recapitulate key features of human tumors. The potential of preclinical models to anticipate treatment efficacy and clinical benefit is also presented,…

0301 basic medicineCancer ResearchPreclinical modelsMedical OncologyBioinformaticsModels Biological03 medical and health sciences0302 clinical medicineCell Line TumorNeoplasmsGeneticsAnimalsHumansMedicinePrecision Medicinebusiness.industryOrganoids; Patient-derived xenografts (PDX); Preclinical models; Oncology; Genetics; Cancer ResearchDiagnostic testPrecision medicineKey featuresTreatment efficacy3. Good healthClinical trialOrganoids030104 developmental biologyOncologyPrecision oncologyPatient-derived xenografts (PDX)030220 oncology & carcinogenesisHeterograftsbusinessBiochimica et Biophysica Acta (BBA) - Reviews on Cancer
researchProduct

Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression

2020

Sepsis is a life-threatening condition that occurs when the body responds to an infection damaging its own tissues. Sepsis survivors sometimes suffer from immunosuppression increasing the risk of death. To our best knowledge, there is no ‘gold standard’ for defining immunosuppression except for a composite clinical end point. As the immune system is exposed to epigenetic changes during and after sepsis, research that focuses on identifying new biomarkers to detect septic patients with immunoparalysis could offer new epigenetic-based strategies to predict short- and long-term pathological events related to this life-threatening state. This review describes the most relevant epigenetic mecha…

0301 basic medicineCancer ResearchRNA Untranslatedmedicine.medical_treatmentAdaptive ImmunityBiologyBioinformaticsEpigenesis GeneticHistonesSepsis03 medical and health sciences0302 clinical medicineImmune systemSepsismicroRNAGeneticsmedicineHumansEpigeneticsPathologicalImmunosuppression TherapyEpigenetic biomarkersSeptic shockImmunosuppressionDNA Methylationmedicine.diseaseShock SepticImmunity Innate030104 developmental biology030220 oncology & carcinogenesisBiomarkersEpigenomics
researchProduct

Molecular pathway activation – New type of biomarkers for tumor morphology and personalized selection of target drugs

2018

Anticancer target drugs (ATDs) specifically bind and inhibit molecular targets that play important roles in cancer development and progression, being deeply implicated in intracellular signaling pathways. To date, hundreds of different ATDs were approved for clinical use in the different countries. Compared to previous chemotherapy treatments, ATDs often demonstrate reduced side effects and increased efficiency, but also have higher costs. However, the efficiency of ATDs for the advanced stage tumors is still insufficient. Different ATDs have different mechanisms of action and are effective in different cohorts of patients. Personalized approaches are therefore needed to select the best ATD…

0301 basic medicineCancer ResearchSystems biologymutation profilingAntineoplastic AgentsComputational biologyProteomics03 medical and health sciencesNeoplasmsmicroRNABiomarkers TumorHumanscancerMedicineMolecular Targeted TherapyEpigeneticsPrecision MedicineBiomedicinebusiness.industryGene Expression ProfilingCancerbioinformaticsmedicine.diseasePrecision medicinesignaling pathwaysGene Expression Regulation NeoplasticGene expression profilingmachine learning030104 developmental biologyCommentarybusinessSignal TransductionSeminars in Cancer Biology
researchProduct

Hormone Involvement in Tissue Development, Physiology and Oncogenesis: A Preface to the Special Issue

2020

Hormones, i.e., the products of specialized endocrine cells which spread throughout the body via the bloodstream, control the normal development and growth of organisms at the embryo-fetal stage and, in adult life, regulate, integrate, and coordinate a range of different physiological processes which concern virtually all body tissues. They exert their biological effects by interacting with either surface or intracellular receptors, thereby activating signalization pathways [1]. For example, steroid hormones, such as those released by the adrenal glands, testes and ovaries, once freely crossed through the plasmalemma, bind to receptors that act as ligand-dependent transcriptional regulators…

0301 basic medicineCancer Researchbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease_causeBioinformaticslcsh:RC254-282hormones development physiology oncogenesis03 medical and health sciencesEditorialn/a030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesismedicineSettore BIO/06 - Anatomia Comparata E CitologiaCarcinogenesisbusinessHormoneCancers
researchProduct

Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment

2015

Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cel…

0301 basic medicineCancer Researchmedicine.medical_treatmentCellOsteoclastsAntineoplastic AgentsCD8-Positive T-LymphocytesBiologyBioinformaticsT-Lymphocytes RegulatoryImmunomodulation03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemBone MarrowDrug DiscoverymicroRNAmedicineHumansMultiple myelomamiRNAPharmacologyImmune-responseTumor immunology.MacrophagesMicroRNADendritic CellsImmunotherapyTh1 CellsPlasma cell neoplasmmedicine.diseaseGene Expression Regulation NeoplasticKiller Cells NaturalMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunotherapyBone marrowMultiple MyelomaReprogrammingCurrent Cancer Drug Targets
researchProduct

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics

2020

Summary Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), the first immune checkpoint to be targeted clinically, has provided an effective treatment option for various malignancies. However, the clinical advantages associated with CTLA-4 inhibitors can be offset by the potentially severe immune-related adverse events (IRAEs), including autoimmune thyroid dysfunction. To investigate the candidate genes and signaling pathways involving in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy, integrated differentially expressed genes (DEGs) were extracted from the intersection of genes from Gene Expression Omnibus (GEO) datasets and text mining. The functional enrichment was perfo…

0301 basic medicineCandidate geneCD74Signaling pathway.FCGR2BDifferentially expressed geneBiologyBioinformaticsHyperthyroidismAutoimmune Diseases03 medical and health sciencesMice0302 clinical medicineHypothyroidismmedicineAnimalsHumansPharmacology (medical)CTLA-4 AntigenProtein Interaction MapsKEGGGeneImmune Checkpoint InhibitorsPharmacologyPreclinical StudiesSignaling pathwayCancerComputational Biologymedicine.diseaseImmune checkpointGene Expression Regulation Neoplastic030104 developmental biologyGene OntologyAutoimmune thyroid dysfunctionOncologyCTLA-4030220 oncology & carcinogenesisDifferentially expressed genesCTLA-4BiomarkersImmune checkpoint blockadeSignal Transduction
researchProduct

Evaluation of in vivo and in vitro models of toxicity by comparison of toxicogenomics data with the literature.

2017

Toxicity affecting humans is studied by observing the effects of chemical substances in animal organisms (in vivo) or in animal and human cultivated cell lines (in vitro). Toxicogenomics studies collect gene expression profiles and histopathology assessment data for hundreds of drugs and pollutants in standardized experimental designs using different model systems. These data are an invaluable source for analyzing genome-wide drug response in biological systems. However, a problem remains that is how to evaluate the suitability of heterogeneous in vitro and in vivo systems to model the many different aspects of human toxicity. We propose here that a given model system (cell type or animal o…

0301 basic medicineCandidate geneCell typeDrug Evaluation PreclinicalBiologyBioinformaticsToxicogeneticsGeneral Biochemistry Genetics and Molecular BiologyIn vitroRats03 medical and health sciences030104 developmental biologyIn vivoToxicityHepatocytesAnimalsHumansToxicogenomicsTranscriptomeMolecular BiologyGeneFunction (biology)Cells CulturedMethods (San Diego, Calif.)
researchProduct

Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches.

2019

Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II which causes vasoconstriction. ACE inhibitors reduce blood pressure by inhibiting ACE. A well-known adverse drug reaction to ACE inhibitors is ACE inhibitor-induced angioedema (ACEi-AE). Angioedema is a swelling of skin and mucosa, which can be fatal if the airway is compromised. We have performed a systematic review of the evidence suggesting that genetic polymorphisms are associated with ACEi-AE and evaluated the methodological approaches of the included studies. The Cochrane Database of Systematic Reviews, Google Scholar, and PubMed were searched. Studies investigating the association between genetic markers and…

0301 basic medicineCandidate geneHeredityACE inhibitorsGenome-wide association studyAngiotensin-Converting Enzyme InhibitorsBioinformatics030226 pharmacology & pharmacyBiochemistryDatabase and Informatics Methods0302 clinical medicineOutcome Assessment Health CareMedicine and Health SciencesDatabase SearchingMultidisciplinarybiologyQRDrugsEnzyme inhibitorsGenomicsResearch AssessmentGenetic MappingSystematic reviewResearch DesignMedicinemedicine.symptomResearch ArticleSystematic ReviewsScienceResearch and Analysis Methods03 medical and health sciencesAdverse ReactionsGenetic predispositionmedicineGenome-Wide Association StudiesGeneticsHumansGenetic Predisposition to DiseaseAngioedemaPharmacologyEvolutionary BiologyPolymorphism GeneticAngioedemaBiology and life sciencesPopulation Biologybusiness.industryCase-control studyComputational BiologyCorrectionAngiotensin-converting enzymeHuman GeneticsGenome AnalysisAngiotensin II030104 developmental biologyHaplotypesCase-Control Studiesbiology.proteinEnzymologyGenetic PolymorphismbusinessPopulation GeneticsPloS one
researchProduct